

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Christopher Wheeler *et al.*      Examiner: To be assigned  
Serial No.: 10/575,438      Group Art Unit: 1642  
Filed: April 11, 2006      Docket: 67789-570  
Title: SYSTEM AND METHOD FOR THE TREATMENT OF CANCER,  
INCLUDING CANCERS OF THE CENTRAL NERVOUS SYSTEM

---

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the referenced materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and that documents listed on the attached PTO/SB/08a Form be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request a copy of the PTO/SB/08a Form be initialed as being considered by the Examiner and returned to the Applicants with the next official communication.

No fee is due pursuant to 37 C.F.R. §1.97(b)(3). If additional fees are believed necessary, the Commissioner is authorized to charge any deficiency or credit any overpayment to Deposit Account No. 04-0258.

**Information Disclosure Statement**

**Page 2**

Serial No.: 10/575,438

Docket No. 67789-570

Filing Date: April 11, 2006


Title: SYSTEM AND METHOD FOR THE TREATMENT OF CANCER,  
INCLUDING CANCERS OF THE CENTRAL NERVOUS SYSTEM

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

April 30, 2007

Respectfully submitted,  
Christopher Wheeler *et al.*  
DAVIS WRIGHT TREMAINE LLP

By

  
Linda B. Truong  
Registration No. 56,461

865 South Figueroa Street  
Suite 2400  
Phone: (213) 633-6800  
Facsimile: (213) 633-6899

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTQ

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use as many sheets as necessary.)*

She

T

1

Complete if Known	
Application Number	10/575,438
Filing Date	April 11, 2006
First Named Inventor	Christopher Whee
Art Unit	1642
Examiner Name	To be assigned
Attorney Docket Number	67789-570

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant." Applicant's unique citation designation number (optional). "See Kind Codes of USPTO Patent Documents at [uspto.gov](http://uspto.gov) or MPEP 901.4." Enter Office that issued the document, by the two-letter code (MPO) Standard ST.3." For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible." Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. The burden estimate includes the time spent to research the completed application by the USPTO and the time spent by the individual case. All comments and suggestions are welcome. If you have any comments or suggestions for reducing burden, please send an e-mail to usptoburden@uspto.gov. Comments can also be mailed to: Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMMBRFS TO THIS ADDRESS.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

2

**Complete if Known**

<i>Application Number</i>	10/575,438
<i>Filing Date</i>	April 11, 2006
<i>First Named Inventor</i>	Christopher Wheeler
<i>Art Unit</i>	1642
<i>Examiner Name</i>	To be assigned
<i>Attorney Docket Number</i>	67789-570

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ^	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ^
	9	SHIN et al., Antitumor Effect of Intratumoral Administration Of Dendritic Cell Combination With Vincristine Chemotherapy In A Murine Fibrosarcoma Model, Histology and Histopathology, April 2003, pp. 435-447, 18:2.	
	10	YU et al., Effective Combination of Chemotherapy and Dendritic Cell Administration for the Treatment of Advanced-Stage Experimental Breast Cancer, Clinical Cancer Research, January 2003, pp. 285-294, 9:1.	
	11	TANAKA et al., Intratumoral Injection of Dendritic Cells After Treatment of Anticancer Drugs Induces Tumor-Specific Antitumor Effect In Vivo, International Journal of Cancer, September 20, 2002, pp. 265-269, 101:3.	
	12	GHOSH et al., Dendritic Cell-Based Immunotherapy Combined With Antimony-Based Chemotherapy Cures Established Murine Visceral Leishmaniasis, The Journal of Immunology, June 1, 2003, pp. 5625-5629, 170:11.	
	13	INOUE et al., Dendritic Cell Collected With Tumor Cells Treated With An Anticancer Drug To Induce Tumor Rejection, Surgery Today, April 4, 2003, pp. 269-276, 33:4.	
	14	REICHARDT et al., Ikiotype Vaccination Of Multiple Myeloma Patients Using Monocyte-Derived Dendritic Cells, Haematologica, October 2003, pp. 1139-1149, 88:10.	
	15	CHUI et al., Dendritic Cell Vaccination Following High Dose Chemotherapy With Autologous Stem Cell Support For Breast Cancer: Long-Term Follow-Up, Proceedings of the American Society of Clinical Oncology, June 2003, 22 (ABSTRACT ONLY).	
	16	CASTRO et al., Current and Future Strategies For The Treatment Of Malignant Brain Tumors, Pharmacology & Therapeutics, April 2003, pp. 71-108, 98:1.	
	17	POLLACK et al., Exploitation of Immune Mechanisms in the Treatment of Central Nervous System Cancer, Seminars in Pediatric Neurology, June 2000, pp. 131-143, 7:2.	
	18	YU et al., Vaccination of Malignant Glioma Patients With Peptide-Pulsed Dendritic Cells Elicits Systemic Cytotoxicity and Intracranial T-Cell Infiltration, Cancer Research, February 1, 2001, pp. 842-847, 61:3.	
	19	STEINMAN, R.M., Some Interfaces of Dendritic Cell Biology, Acta Pathologica, Microbiologica, et Immunologica Scandinavica, July 2003, pp. 675-697, 111:7-8.	

Examiner Signature	Date Considered	
--------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^Applicant's unique citation designation number (optional). ^Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.